Page 131 - 2021_06-Haematologica-web

aGvHD impact on endothelium
10. Dumler JS, Beschorner WE, Farmer ER, Di Gennaro KA, Saral R, Santos GW. Endothelial-cell injury in cutaneous acute graft-versus-host disease. Am J Pathol. 1989;135(6):1097-1103.
11.Mir E, Palomo M, Rovira M, et al. Endothelial damage is aggravated in acute GvHD and could predict its development. Bone Marrow Transplant. 2017;52(9):1317- 1325.
12. Rachakonda SP, Penack O, Dietrich S, et al. Single-nucleotide polymorphisms within the thrombomodulin gene (THBD) predict mortality in patients with graft-versus-host disease. J Clin Oncol. 2014;32(30): 3421- 3427.
13. Dietrich S, Falk CS, Benner A, et al. Endothelial vulnerability and endothelial damage are associated with risk of graft- versus-host disease and response to steroid treatment. Biol Blood Marrow Transplant. 2013;19(1):22-27.
14. Andrulis M, Dietrich S, Longerich T, et al. Loss of endothelial thrombomodulin pre- dicts response to steroid therapy and sur- vival in acute intestinal graft-versus-host disease. Haematologica. 2012;97(11):1674- 1677.
15.Pihusch V, Rank A, Steber R, et al. Endothelial cell-derived microparticles in allogeneic hematopoietic stem cell recipi- ents. Transplantation. 2006;81(10):1405- 1409.
16. Rachakonda SP, Dai H, Penack O, et al. Single nucleotide polymorphisms in CD40L predict endothelial complications and mortality after allogeneic stem-cell transplantation. J Clin Oncol. 2018;36(8): 789-800.
17. Luft T, Benner A, Jodele S, et al. EASIX in patients with acute graft-versus-host dis- ease: a retrospective cohort analysis. Lancet Haematol. 2017;4(9):e414-e423.
18. Schmid PM, Bouazzaoui A, Doser K, et al. Endothelial dysfunction and altered mechanical and structural properties of resistance arteries in a murine model of graft-versus-host disease. Biol Blood Marrow Transplant. 2014;20(10):1493- 1500.
19. Lerner KG, Kao GF, Storb R, Buckner CD, Clift RA, Thomas ED. Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors. Transplant Proc. 1974;6(4):367-371.
20. Mertlitz S, Shi Y, Kalupa M, et al. Lymphangiogenesis is a feature of acute GVHD, and VEGFR-3 inhibition protects against experimental GVHD. Blood. 2017;129(13):1865-1875.
21.Riesner K, Kalupa M, Shi Y, Elezkurtaj S, Penack O. A preclinical acute GVHD mouse model based on chemotherapy con- ditioning and MHC-matched transplanta- tion. Bone Marrow Transplant. 2016;51(3):410-417.
22. Bouazzaoui A, Spacenko E, Mueller G, et al. Steroid treatment alters adhesion mole- cule and chemokine expression in experi- mental acute graft-vs.-host disease of the intestinal tract. Exp Hematol. 2011;39(2): 238-249 e231.
23. Toubai T, Rossi C, Tawara I, et al. Murine models of steroid refractory graft-versus- host disease. Sci Rep. 2018;8(1):12475.
24. Beilhack A, Schulz S, Baker J, et al. In vivo analyses of early events in acute graft-ver- sus-host disease reveal sequential infiltra- tion of T-cell subsets. Blood. 2005;106(3): 1113-1122.
25.Radu M, Chernoff J. An in vivo assay to test blood vessel permeability. J Vis Exp. 2013(73):e50062.
26. Brede C, Friedrich M, Jordan-Garrote AL, et al. Mapping immune processes in intact tis- sues at cellular resolution. J Clin Invest. 2012;122(12):4439-4446.
42. Medinger M, Heim D, Gerull S, et al. Increase of endothelial progenitor cells in acute graft-versus-host disease after allo- geneic haematopoietic stem cell transplan- tation for acute myeloid leukaemia. Leuk Res. 2016;47:22-25.
43. Yan Z, Zeng L, Jia L, Xu S, Ding S. Increased numbers of circulating ECs are associated with systemic GVHD. Int J Lab Hematol. 2011;33(5):507-515.
44. Tatekawa S, Kohno A, Ozeki K, et al. A novel diagnostic and prognostic biomarker panel for endothelial cell damage-related complications in allogeneic transplantation. Biol Blood Marrow Transplant. 2016;22(9):1573-1581.
45. Lindas R, Tvedt TH, Hatfield KJ, Reikvam H, Bruserud O. Preconditioning serum lev- els of endothelial cell-derived molecules and the risk of posttransplant complica- tions in patients treated with allogeneic stem cell transplantation. J Transplant. 2014;2014:404096.
46. Biedermann BC, Tsakiris DA, Gregor M, Pober JS, Gratwohl A. Combining altered levels of effector transcripts in circulating T cells with a marker of endothelial injury is specific for active graft-versus-host disease. Bone Marrow Transplant. 2003;32(11): 1077-1084.
47. Penack O, Henke E, Suh D, et al. Inhibition of neovascularization to simultaneously ameliorate graft-vs-host disease and decrease tumor growth. J Natl Cancer Inst. 2010;102(12):894-908.
48.Less JR, Skalak TC, Sevick EM, Jain RK. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res. 1991;51(1):265- 273.
49. Huang Y, Goel S, Duda DG, Fukumura D, Jain RK. Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res. 2013;73(10): 2943-2948.
50. Tornavaca O, Chia M, Dufton N, et al. ZO- 1 controls endothelial adherens junctions, cell-cell tension, angiogenesis, and barrier formation. J Cell Biol. 2015;208(6):821-838.
51. Fanning AS, Little BP, Rahner C, Utepbergenov D, Walther Z, Anderson JM. The unique-5 and -6 motifs of ZO-1 regu- late tight junction strand localization and scaffolding properties. Mol Biol Cell. 2007;18(3):721-731.
52. Umeda K, Ikenouchi J, Katahira-Tayama S, et al. ZO-1 and ZO-2 independently deter- mine where claudins are polymerized in tight-junction strand formation. Cell. 2006;126(4):741-754.
53.Reyat JS, Chimen M, Noy PJ, Szyroka J, Rainger GE, Tomlinson MG. ADAM10- interacting tetraspanins Tspan5 and Tspan17 regulate VE-cadherin expression and promote T lymphocyte transmigration. J Immunol. 2017;199(2):666-676.
54. Vockel M, Vestweber D. How T cells trig- ger the dissociation of the endothelial receptor phosphatase VE-PTP from VE-cad- herin. Blood. 2013;122(14):2512-2522.
55. Zhao Y, Ting KK, Li J, et al. Targeting vas- cular endothelial-cadherin in tumor-associ- ated blood vessels promotes T-cell-mediat- ed immunotherapy. Cancer Res. 2017;77 (16):4434-4447.
56. Schulte D, Kuppers V, Dartsch N, et al. Stabilizing the VE-cadherin-catenin com- plex blocks leukocyte extravasation and vascular permeability. EMBO J. 2011;30 (20):4157-4170.
57. McHale TM, Garciarena CD, Fagan RP, et
27.
Wertheimer T, Velardi E, Tsai J, et al. Production of BMP4 by endothelial cells is crucial for endogenous thymic regenera- tion. Sci Immunol. 2018;3(19):eaal2736.
28. Dietrich S, Okun JG, Schmidt K, et al. High pre-transplant serum nitrate levels predict risk of acute steroid-refractory graft-versus- host disease in the absence of statin thera- py. Haematologica. 2014;99(3):541-547. Luft T, Dietrich S, Falk C, et al. Steroid- refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood. 2011;118(6):1685-1692.
29.
30.
31.
Rotz SJ, Dandoy CE, Davies SM. ST2 and Endothelial injury as a link between GVHD and microangiopathy. N Engl J Med. 2017;376(12):1189-1190.
Vander Lugt MT, Braun TM, Hanash S, et al. ST2 as a marker for risk of therapy-resis- tant graft-versus-host disease and death. N Engl J Med. 2013;369(6):529-539.
32.Balarini CM, Leal MA, Gomes IB, et al. Sildenafil restores endothelial function in the apolipoprotein E knockout mouse. J Transl Med. 2013;11:3.
33. Bivalacqua TJ, Sussan TE, Gebska MA, et al. Sildenafil inhibits superoxide formation and prevents endothelial dysfunction in a mouse model of secondhand smoke induced erectile dysfunction. J Urol. 2009;181(2):899-906.
34.Aksu V, Yuksel V, Chousein S, et al. The effects of sildenafil and n-acetylcysteine on ischemia and reperfusion injury in gastroc- nemius muscle and femoral artery endothe- lium. Vascular. 2015;23(1):21-30.
35. Valatsou A, Briasoulis A, Vogiatzi G, et al. Beneficial effects of sildenafil on tissue per- fusion and inflammation in a murine model of limb ischemia and atherosclerosis. Curr Vasc Pharmacol. 2017;15(3):282-287.
36. Fahning BM, Dias AT, Oliveira JP, et al. Sildenafil improves vascular endothelial structure and function in renovascular hypertension. Curr Pharm Biotechnol. 2015;16(9):823-831.
37. McLaughlin K, Lytvyn Y, Luca MC, Liuni A, Gori T, Parker JD. Repeated daily dosing with sildenafil provides sustained protec- tion from endothelial dysfunction caused by ischemia and reperfusion: a human in vivo study. Am J Physiol Heart Circ Physiol. 2014;307(6):H888-894.
38.Yin J, Kukucka M, Hoffmann J, et al. Sildenafil preserves lung endothelial func- tion and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure. Circ Heart Fail. 2011;4(2):198-206.
39.Yaguas K, Bautista R, Quiroz Y, et al. Chronic sildenafil treatment corrects endothelial dysfunction and improves hypertension. Am J Nephrol. 2010;31(4): 283-291.
40. Almici C, Skert C, Bruno B, et al. Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell trans- plantation. Bone Marrow Transplant. 2017;52(12):1637-1642.
41. Woywodt A, Scheer J, Hambach L, et al. Circulating endothelial cells as a marker of endothelial damage in allogeneic hematopoietic stem cell transplantation. Blood. 2004;103(9):3603-3605.
haematologica | 2021; 106(8)
2159